Skip To Content
Get Our Newsletter
JEWISH. INDEPENDENT. NONPROFIT.

Support the Forward

Funded by readers like you DonateSubscribe
Fast Forward

23andMe Can Now Test Your DNA For Breast Cancer Risk

23andMe recently received FDA approval to inform customers of its popular mail-in DNA tests about their risk for breast cancer, the Atlantic reported. 23andMe is the first company to get federal approval for a direct-to-consumer genetic cancer risk test.

The FDA sanctioned 23andMe’s request to tell customers whether they have mutations on the genes BRCA-1 or BRCA-2 genes — mutations that are strongly linked to the development of breast cancer.

Another Silicon Valley company, Color Genomics, launched a similar breast cancer genetics test in 2015. But the company — owned by an Israeli — was only allowed to sell its mail-in test through physicians.

23andMe used to offer BRCA tests when it first was founded, but was forced to suspend all its genetic health testing by the FDA in 2013.

“Worrying about the many current 23andMe customers who have one of or more of these variants has caused me sleepless nights,” 23andMe CEO Anne Wojcicki wrote in a blog post Tuesday.

BRCA gene mutations mainly affect women, and certain variants of the mutation can increase risk of breast and ovarian cancer by nearly 50%.

Contact Ari Feldman at feldman@forward.com or on Twitter @aefeldman

Engage

  • SHARE YOUR FEEDBACK

  • UPCOMING EVENT

    NY-12 Candidate Forum

    THE TEMPLE EMANU-EL STREICKER CENTER and Virtual

    Aug 10, 2022

    7 pm ET · 

    Will the last Jew left in New York’s congressional delegation be reelected? Will New York’s senior congresswoman receive another term? Or will one of the newcomers upend Manhattan politics?

Republish This Story

Please read before republishing

We’re happy to make this story available to republish for free under an Attribution-Non Commercial-No Derivatives Creative Commons license as long as you follow our republishing guidelines, which require that you credit the Foward and retain our pixel. See our full guidelines for more information.

To republish, copy the HTML, which includes our tracking pixel, all paragraph styles and hyperlinks, the author byline, images, and credit to the Foward. Have questions? Please email us at editorial@forward.com.

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.